Tetrous — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Tetrous is a medical technology company pioneering a novel approach to bone-to-tendon healing with its EnFix® product, a biologic scaffold designed to treat Enthesis Failure Syndrome. The company targets the substantial and underserved rotator cuff repair market, where failure rates range from 20% to 70%. Its technology leverages proprietary demineralized bone fiber processing (Bone Textile™) and shape-retention (FormLok™) to create a surgeon-friendly implant that promotes natural tissue regeneration. Led by an experienced entrepreneur and supported by clinical validation, Tetrous is positioned to commercialize a differentiated solution in sports medicine.

OrthopedicsSports Medicine

Technology Platform

Proprietary demineralized bone matrix (DBM) processing technologies: Bone Textile™ creates long, strong, interwoven DBM fibers for enhanced cell integration; FormLok™ provides shape retention for ease of use in arthroscopic surgery.

Opportunities

The $3B+ annual rotator cuff repair market, with failure rates of 20-70%, represents a massive and underserved clinical need.

Success with EnFix® could establish a new standard of care for interface healing and enable expansion into other tendon/ligament repair markets like ACL and Achilles.

Risk Factors

Key risks include achieving regulatory clearance, driving surgeon adoption against established practices, and competing with large, well-funded orthopedic companies.

The company's future is heavily reliant on the clinical and commercial success of its single lead product.

Competitive Landscape

Competition includes large orthopedic giants (Zimmer Biomet, Stryker) offering biologic patches and scaffolds, and smaller biotech firms focused on regenerative solutions. Tetrous differentiates by specifically targeting the enthesis interface with a surgeon-friendly, fiber-based DBM scaffold, rather than offering a general tendon reinforcement patch.

More companies in Biologics / Biosimilars →More companies in United States →